SCM
CASI

Southport Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

Southport Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed – – 203
2016
Q2 		$0 Buy
+2
New +$25 ﹤0.01% 533

Other funds holding CASI

WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Southport Capital Management's CASI Position: Q3 2016 in Review

Southport Capital Management sold out of CASI Pharmaceuticals (CASI) in Q3 2016, closing a stake of 2 shares.

Southport Capital Management first reported a position in CASI in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 29 funds tracked by Wall St. Rank hold CASI as of Q3 2016.

  • Southport Capital Management reported no remaining CASI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Southport Capital Management sold 2 CASI Pharmaceuticals shares in Q3 2016.
  • Southport Capital Management first reported a position in CASI Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Southport Capital Management's CASI Pharmaceuticals position peaked at $0 in Q2 2016.
  • 29 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2016.

Based on Southport Capital Management's 13F filing for Q3 2016, filed 19 Oct 2016.